Description: Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza, as well as SemaThera Inc. to develop biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors. The company was founded in 1896 and is headquartered in Basel, Switzerland.
Home Page: www.roche.com
Grenzacherstrasse 124
Basel,
4058
Switzerland
Phone:
41 61 688 11 11
Officers
| Name | Title |
|---|---|
| Dr. Severin Schwan Ph.D. | Executive Chairman |
| Dr. Thomas Schinecker | Chief Executive Officer |
| Dr. Alan Hippe | Chief Financial & Information Officer |
| Dr. Bruno Eschli | Head of Investor Relations |
| Ms. Claudia Bockstiegel | General Counsel |
| Ms. Pascale Schmidt | Chief Compliance Officer |
| Ms. Barbara Schadler | Head of Group Communications |
| Ms. Cristina A. Wilbur | Chief People Officer |
| Dr. Nicolas Dunant | Head of Group Media Relations |
| Mr. Boris L. Zaitra | Head of Corporate Business Development |
Exchange: OTCQX
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 12.1212 |
|---|---|
| Trailing PE: | 19.6804 |
| Price-to-Book MRQ: | 7.018 |
| Price-to-Sales TTM: | 3.8441 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 103605 |